CONSENSUS STATEMENT

Strengthening Injecting-Related Harm Reduction in Prisons

Harm reduction in Prisons Working Group, March 2023

- People in prison inject illicit drugs, and experience significant harms.
- Injecting-related harms in prisons can be prevented.
- This consensus statement summarises the evidence about how to prevent those harms.
- Endorsed by the 29 members of the Harm Reduction in Prisons Working Group, this statement provides the basis for effective action to eliminate injecting-related harms in prisons.

This statement was drafted by the Harm Reduction in Prisons Working Group¹ to provide a clear and concise overview of the evidence-based harm reduction interventions needed to reduce injecting-related harms in Australian prisons. Australian government commitments to eliminating hepatitis C by 2030 have increased attention on elimination strategies and prisons have been identified as a key setting for intervention. The harm reduction strategies outlined in this statement are critical in achieving this commitment, but importantly, have application for all people at risk of injecting-related harm, disease and death in prisons. It is hoped that this statement can assist policy makers at all levels of government in all jurisdictions to apply a broader lens to harm reduction and to understand why a comprehensive response is needed.

What is injecting-related harm reduction in prison?

Injecting drug use can result in a number of fatal or serious harms including overdose, blood-borne virus transmission and injecting-related injuries. There is a wealth of evidence that injecting-related prison harm reduction programs can reduce the transmission of blood-borne viruses, reduce risk behaviours, reduce death and can even improve prison safety and reduce rates of reoffending (1-4).

Harm reduction is a practice that supports people to improve their health through non-judgemental support. Harm reduction programs, policies and practices aim to reduce the health harms related to injecting drug use, including blood-borne virus infection, drug overdose and injecting injuries. All three of these harms are preventable with effective harm reduction programs. Harm reduction programs provide interventions that support the person where they are at, and are grounded in principles of justice, human rights and equity. They are an approach that is effective at reaching some of the most marginalised members of society who may not otherwise have access to healthcare.

Why is injecting-related harm reduction in prisons important?

1. People who are imprisoned have a much higher rate of harmful outcomes from injecting drug use than the general population

People in prison have much higher rates of injecting drug use than the general population with almost half of new prison entrants reporting a history of injecting drug use (5, 6). Despite attempts

¹ See the end of this document for details about the Harm Reduction in Prisons Working Group.
to prevent drug use and supply in prison, the use of drugs, including injecting drug use, remains common (5, 7-9). There is also evidence that some people start injecting drugs or reinitiate previous injecting drug use while in prison (8, 10).

Additionally, prisons are high-risk environments for injecting-related harms, such as hepatitis C, due to a lack of access to harm reduction programs, including the provision of new and sterile injecting equipment (11-14). Where people in prisons do not have access to needle and syringe programs, sharing of injecting equipment between people who inject drugs is common (15-17). It can also lead to the creation of homemade injecting equipment using unsterile items found in prison (18).

Due to these factors, people in prison experience much higher rates of blood-borne viruses, including hepatitis C and HIV, than the general population (19, 20). Lack of access to sterile and new injecting equipment also puts people at risk of highly complex injecting-related injuries and disease, such as septicaemia, vascular damage and thrombophlebitis (21).

2. Access to harm reduction in prison decreases the risk of injury and disease from injecting drug use

While medication exists to treat most blood-borne viruses, reinfections will continue to occur while people in prison lack access to new and sterile injecting equipment (22, 23). Evidence on hepatitis C is a good example of this. Australia has a goal of eliminating hepatitis C by 2030. The introduction of direct-acting antiviral medicines has seen a significant reduction in the rates of hepatitis C infections in Australia, however new hepatitis C infections and reinfections are occurring in Australian prisons (24, 25). People in prisons need access to harm reduction programs, in addition to treatment, to eliminate hepatitis C and stop the spread of other blood-borne viruses and injecting-related injury and disease (26, 27).

3. People in prison have the right to access safe and effective harm reduction and healthcare

All people are entitled to the highest level of attainable healthcare, regardless of whether they are in prison or in the community. This is a basic human right. International law through the United Nations Standard Minimum Rules for the Treatment of Prisoners (the Mandela Rules), and the Australian Government’s Guiding Principles for Corrections in Australia both require healthcare in prisons to be equivalent to that in the community (28).

4. Prison provides an opportunity to support marginalised and vulnerable populations with harm reduction interventions

The health needs of people in prison in Australia can be significant and complex and often long-term and chronic in nature (5). People in prison often represent some of the most vulnerable and disadvantaged community members (2) and prison populations often have high rates of trauma, mental illness, chronic disease and cognitive disability, and are disproportionality affected by the social determinants of health (29). They are also less likely to be connected to healthcare services (30).

Prison settings therefore provide an opportunity to engage with people who have a history of injecting drug use, provide harm reduction interventions and facilitate access to other healthcare services which they may not have accessed in the community (31). Prisons can also provide opportunities to link people after their release with health and community services that provide support and promote wellbeing (32). Providing harm reduction services in prisons therefore not only benefits people who access those services, but also improves prison safety and the health of their communities after release (29, 33).
What interventions are effective at reducing injecting-related harm?

Harm reduction interventions encourage safer behaviours and practice and reduce preventable risk factors. There are also interventions that reduce harms that are standard healthcare - for instance, the testing and treatment for blood-borne viruses is standard healthcare and it also reduces one of the harms from drug use. What is important is providing a full suite of harm reduction interventions. Cherry-picking harm reduction responses seriously limits effectiveness with the best results of many harm reduction interventions working in tandem (e.g. through the synergistic provision of opioid agonist treatment and needle exchange programs, or peer education to prevent blood-borne virus infection/reinfection alongside effective blood-borne virus treatment).

Harm reduction should also be considered along a continuum of complementary approaches and be provided throughout the carceral journey from entry through to release (2). Table 1 below lists interventions for preventing injecting-related harms that have proven effective and are freely available in the community. All the interventions listed should form part of a suite of standard interventions at all adult prison facilities across Australia. All people in prison in Australia should be free to choose which of the following interventions are most suitable for them and whether or not to engage in harm reduction.

Who supports prison harm reduction and how does it fit with our international and national obligations?

The United Nations and the World Health Organization have called for greater harm reduction in prisons, noting the important role of harm reduction interventions in both the response to people who use alcohol and other drugs, and in the prevention of blood-borne viruses. Several reports and guidelines suggest a comprehensive package of interventions to reduce harms for people in and exiting prison, including needle and syringe programs and opioid agonist treatment (2, 12, 34-37).

Australia has five national blood-borne virus and sexually transmitted infection (STI) strategies that all recognise people in prison as a priority population, prisons as a priority setting for interventions, or both. Greater access to interventions which prevent or reduce the harms from drug use are supported in all the strategies. Increasing availability and distribution of sterile needles and syringes, pharmacotherapy and peer-based education are variously supported by the strategies on hepatitis B, hepatitis C, HIV and the blood-borne virus and STI strategy for Aboriginal and Torres Strait Islanders (38-41).

Harm reduction is also one of three pillars in the National Drug Strategy 2017-2026 alongside demand reduction and supply reduction (42). People in contact with the criminal justice system are identified as a priority population for harm reduction strategies that encourage safer behaviours, such as needle and syringe programs. The National Prisons Hepatitis Network statement on management of hepatitis C in prisons calls for the scale up of harm reduction in order to prevent hepatitis C infections and reinfection (11). This includes the provision of regulated needle and syringe programs, and greater access to the full range of opioid agonist treatment options (11).

---

### Table 1: Interventions to reduce injecting-related harms

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Harms prevented or reduced</th>
<th>Evidence of effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Needle syringe programs (NSPs): regulated provision of sterile injecting equipment to people who inject drugs</strong></td>
<td>Blood-borne virus transmission</td>
<td>A wealth of evidence demonstrates NSPs work in reducing transmission of blood-borne viruses, particularly when implemented in combination with opioid agonist treatment (OAT) (43). The provision of prison NSPs is considered best practice for blood-borne virus and alcohol and other drug-related harm reduction (44). Evidence emerging from the 10 countries that operate at least one prison NSP show that they are feasible and likely to reduce blood-borne viruses in prisons just as they do in the community (45, 46). The lack of regulated access to sterile injecting equipment is associated with new blood-borne virus infections and reinfections among prison populations despite the provision of direct-acting antivirals (22-25, 27). Regulating access to new sterile needles is also an important strategy in preventing injecting-related injuries and disease and thrombophlebitis (21).</td>
</tr>
<tr>
<td><strong>Overdose prevention sites</strong></td>
<td>Overdose Blood-borne virus transmission Injecting-related injury and disease</td>
<td>Overdose prevention sites provide a safer place for people to inject drugs under the supervision of health professionals where overdose can be rapidly reversed. These sites also provide opportunities for people who inject drugs to meet and talk with health professionals and be referred to other services. Recorded outcomes from community overdose prevention sites in Australia and internationally demonstrate that they reduce the risk of overdose and improve access to care (47).</td>
</tr>
<tr>
<td><strong>Needle cleaning agents</strong></td>
<td>Blood-borne virus transmission Injecting-related injury and disease</td>
<td>Bleach is an effective agent against the hepatitis C virus and HIV when it can be used properly to clean needles and syringes (48). In prison settings, needle cleaning agents have less evidence that they prevent infections because of the prison environment preventing timely cleaning (due to urgency/fear of detection) and/or lack of access to cleaning agents, or where a needle and syringe is shared by multiple people (17, 49). Where people in prisons cannot access clean and sterile injecting equipment, needle cleaning agents should be provided.</td>
</tr>
<tr>
<td><strong>Naloxone provision</strong></td>
<td>Overdose</td>
<td>Naloxone is a drug that temporarily reverses opioid overdose or adverse reaction. It can be administered by an intranasal spray or via injection. Take home naloxone programs train participants in recognising overdose and administering naloxone. Evidence shows that these</td>
</tr>
<tr>
<td>Interventions</td>
<td>Harms prevented or reduced</td>
<td>Evidence of effectiveness</td>
</tr>
<tr>
<td>---------------------------------------------------</td>
<td>------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Education and information</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-led education and programs</td>
<td>Injecting-related injury and disease</td>
<td>Harm reduction education provides information to people about safer drug use practices. There is extensive research that shows education programs in prison are more likely to be effective at reducing risky behaviours where they are developed and delivered by peers, with peer educators a more credible and trusted source of information for people in prison (3, 53). Peer support programs and peer workers can also provide emotional support and practical information, for instance in supporting engagement in testing (54, 55).</td>
</tr>
<tr>
<td></td>
<td>Overdose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blood-borne virus transmission</td>
<td></td>
</tr>
<tr>
<td><strong>Opioid Agonist Treatment (OAT)</strong></td>
<td></td>
<td>OAT is a cost-effective treatment that is associated with reductions in harmful drug use, blood-borne infections and death, both in the community and in prison (56-58). OAT has also been found to improve prison safety and reduced rates of re-offending among people in prison (3). Combined use of OAT with needle syringe programs is more effective at preventing new blood-borne virus infections than just providing OAT alone (43).</td>
</tr>
<tr>
<td></td>
<td>Blood-borne virus transmission</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Injecting-related injury and disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Overdose</td>
<td></td>
</tr>
<tr>
<td><strong>Blood-borne virus (BBV) screening</strong></td>
<td></td>
<td>Prison is an independent risk factor for contracting blood-borne viruses; all people in prison should be offered testing (11). The ECDC, EMCDDA and WHO all suggest that testing for BBVs should be offered to everyone on entry to prison and then at regular intervals (yearly), and be voluntary (20). International research suggests that opt-out systems (whereby screening is standard practice for everyone unless they object), rather than opt-in (whereby screening has to be requested or offered individually following the establishment of relevant risk factors) is best for maximum take-up of screening, as long as people are adequately informed of their right to refuse (59, 60).</td>
</tr>
<tr>
<td></td>
<td>Blood-borne virus transmission</td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis B virus (HBV) vaccination</strong></td>
<td></td>
<td>HBV immunisation reduces the pool of people infected with HBV thereby reducing the likelihood of transmission, known as treatment as prevention. HBV vaccination of all people in prison is recommended by the Australian government (61).</td>
</tr>
<tr>
<td></td>
<td>Blood-borne virus transmission</td>
<td></td>
</tr>
<tr>
<td><strong>Hepatitis C virus (HCV) treatment</strong></td>
<td></td>
<td>Direct Acting Antivirals (DAA) are an approved medication that have special prescribing status so can be accessed by people in prison under Medicare. The provision of unrestricted access to</td>
</tr>
</tbody>
</table>
### Interventions

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Harms prevented or reduced</th>
<th>Evidence of effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAAs</td>
<td></td>
<td>DAAs has cured nearly half of all people living with hepatitis C in Australia (from 2016 to 2020) and has reduced incidence of new hepatitis C infections in Australia (26).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>However, DAAs are less effective as a treatment as prevention strategy in contexts where there are high rates of risky injecting behaviour and other harm reduction is unavailable. DAA treatment needs to be combined with effective primary preventative measures (such as needle exchange programs) to achieve hepatitis C elimination (24, 26, 27, 39).</td>
</tr>
<tr>
<td>HIV prevention and treatment</td>
<td>Blood-borne virus transmission</td>
<td>Pre-Exposure Prophylaxis (PrEP) is a medication that can be taken to prevent HIV acquisition and Post-Exposure Prophylaxis (PEP) is a course of medication that can be taken after potential exposure to HIV to prevent acquisition. Antiretroviral Therapy (ART) is an approved medication to treat HIV. PrEP, PEP and ARTs are approved medications in Australia that are funded on the Pharmaceutical Benefits Scheme.</td>
</tr>
</tbody>
</table>
About the Harm Reduction in Prisons Working Group

During 2019 a group of concerned practitioners, researchers and advocates came together to discuss the current state of harm reduction in prisons in Australia. From that initial meeting, an informal working group was formed with a purpose of advancing and achieving the elimination of hepatitis C and other blood-borne viruses in Australian prisons. Today, the Harm Reduction in Prisons Working Group continues to operate in an informal capacity, but since that first meeting has grown to include individuals and organisations in every state and territory in Australia and also New Zealand.

We see this statement as the beginning of a dialogue, and it presents a telegraphic summary of injecting-related harm reduction in prisons (not delving into the nuanced and detailed perspectives of all the stakeholders involved in its development). The following members of the Harm Reduction in Prisons Working Group were involved in drafting this statement and endorse it:

Professor Alison Ritter AO, Drug Policy Modelling Program, Social Policy Research Centre, UNSW Sydney
Liz Barrett, Drug Policy Modelling Program, Social Policy Research Centre, UNSW Sydney
Geoff Davey, CEO, QuHVN
Adrian Gorringe, Australian Injecting and Illicit Drug Users League (AIVL), ACT
Anshul Kaul, NT
Dr James Blogg, Senior Staff Specialist, NSW
Jenny Grant, Hepatitis SA
Dr Lise Lafferty, Centre for Social Research in Health, UNSW Sydney
Professor Greg Dore, Kirby Institute, UNSW Sydney
Dr Michael Levy AM, Public Health Physician, ACT
John Ryan, CEO, Penington Institute, VIC
Dr Mary Harrod, NSW Users and AIDS Association
Sione Crawford, Harm Reduction Victoria
Stuart Loveday, NSW
The Board of Hepatitis NSW
Colette Mcgrath, Service Director, Population Health, Justice Heath and Forensic Mental Health Network, NSW
Tracey Brown, Programs Manager, Population Health, Justice Heath and Forensic Mental Health Network, NSW
Tom Wright, Harm Reduction Coordinator, Population Health, Justice Health and Forensic Mental Health Network, NSW
Sujay Kentyn, NT
Dr Joy Rowland, Director Medical Services, Health Services, Department of Justice, WA
Holly Beasley, Senior Project Officer (BBV), Health Services, Department of Justice, WA
Jill Mackenzie, Senior Project Officer (BBV), Health Services, Department of Justice, WA
Professor Kate Dolan, Harm Reduction Australia, Sydney
Jason George, Harm Reduction Lead, NZ Needle Exchange Program
Melanie Walker, CEO, Australian Alcohol and Other Drugs Council
Professor Mark Stoové, Head of Public Health, Burnet Institute, VIC
Angela Corry, CEO, Peer Based Harm Reduction WA
Carrie Fowlie, CEO, Hepatitis Australia
John Didlick, Policy Analyst, Hepatitis Australia

The secretariat of the Harm Reduction in Prisons Working Group is the Drug Policy Modelling Program, UNSW, please contact Liz Barrett (liz.barrett@unsw.edu.au) for more information.
References

37. WHO. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Switzerland; 2016.
44. UNODC. A handbook for starting and managing needle and syringe programmes in prisons and other closed settings. Vienna; 2014.


60. AASLD, IDSA. HCV testing and treatment in correctional settings. United States; 2019.